Verne Expands Helsinki Data Center Campus With Strategic Site Acquisition
6.2.2025 10:00:00 EET | Business Wire | Press release
Verne, the leading provider of sustainably powered HPC data centers across the Nordics, has acquired the land at its existing Helsinki data center campus, securing room for future expansion. This purchase marks another milestone in Verne’s ambitious growth strategy for the Nordics, following the recent announcement of its new facility to be built in Mäntsälä, Finland.
Room to grow
Verne plans to develop the site further, leveraging its 70MW capacity to meet the increasing demand for sustainable, high-performance compute infrastructure. The land was acquired from Onvest, a family-owned company with a long history in the region.
The existing site in Helsinki currently serves a number of high-profile multinational customers. Its strategic location provides excellent connectivity to power and fibre networks, proximity to Helsinki Airport, and easy access to the city centre – making it ideal for organisations across industries looking for reliable, accessible, and well-connected facilities.
Designed with high-density compute in mind, the planned expansion will include two new buildings fully equipped to meet the technical requirements of AI, HPC, and other intensive workloads.
Sustainability at the core
Verne remains committed to sustainability, with the Helsinki campus running on 100 percent renewable energy. Waste heat generated by the data center is repurposed through a direct connection to the local district heating network.
All new facilities will be built to support liquid cooling, enabling efficient management of the high heat levels generated by AI and other intensive compute workloads. This design makes the existing heat reuse infrastructure even more vital, facilitating the effective capture and repurposing of waste heat.
Additionally, Verne uses renewable diesel for its backup power generators in Finland, reducing greenhouse gas emissions from the generators by an average of 90 percent.
“The acquisition of this site reinforces Verne’s long-term commitment to Finland and provides an even stronger foundation for our continued growth in the region,” said Dominic Ward, CEO of Verne. “We’ve seen a huge uplift in demand, and having successfully operated from this location for a number of years, we are well-positioned to scale our capabilities and continue delivering industry-leading, sustainable data center solutions to support the next generation of AI and high-performance computing.”
For more information, visit: www.verneglobal.com
About Verne
Verne provides sustainable data center services that enable organisations to cost-effectively scale their digital infrastructure while reducing their environmental impact. The company’s four Nordic data centers, located in Iceland and Finland, are powered by 100 percent renewable energy, optimised for high-performance computing (HPC), artificial intelligence (AI) and other intensive workloads, and supported by a dedicated team of onsite experts. Verne also operates a hyper-connected data center in central London, which serves as a strategic hub for applications requiring low latency and robust connectivity.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250206553002/en/
Contacts
Press contacts
Evie Ashby / Michelle Edge
Eleven Hundred Agency
T: +44(0)20 7688 5202
E: eha@verneglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom